NASDAQ: PSNLPersonalis Inc Stock
$2.68-0.05 (-1.83%)
Updated Mar 20, 2023
PSNL Price
$2.68
Fair Value Price
$4.63
Market Cap
$125.25M
52 Week Low
$1.73
52 Week High
$8.96
P/E
-1.08x
P/B
0.57x
P/S
1.39x
PEG
N/A
Dividend Yield
N/A
Revenue
$65.05M
Earnings
-$113.32M
Gross Margin
20.5%
Operating Margin
-173.83%
Profit Margin
-174.2%
Debt to Equity
0.34
Operating Cash Flow
-$70M
Beta
1.51
Next Earnings
May 2, 2023
Ex-Dividend
N/A
Next Dividend
N/A
PSNL Overview
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PSNL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PSNL ($2.68) is undervalued by 42.12% relative to our estimate of its Fair Value price of $4.63 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
PSNL ($2.68) is significantly undervalued by 42.12% relative to our estimate of its Fair Value price of $4.63 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
PSNL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PSNL due diligence checks available for Premium users.
Be the first to know about important PSNL news, forecast changes, insider trades & much more!
PSNL News
Valuation
PSNL fair value
Fair Value of PSNL stock based on Discounted Cash Flow (DCF)
Price
$2.68
Fair Value
$4.63
Undervalued by
42.12%
PSNL ($2.68) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PSNL ($2.68) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PSNL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PSNL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.08x
Industry
33.27x
Market
22.37x
PSNL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.57x
Industry
4.13x
PSNL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PSNL's financial health
Profit margin
Revenue
$16.7M
Net Income
-$31.1M
Profit Margin
-185.8%
PSNL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PSNL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$292.7M
Liabilities
$74.6M
Debt to equity
0.34
PSNL's short-term assets ($199.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PSNL's short-term assets ($199.70M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PSNL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PSNL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.8M
Investing
$21.9M
Financing
$511.0k
PSNL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PSNL vs Diagnostic & Research Stocks
Personalis Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.